• Sycamore Partners is reportedly in talks to sell U.K. pharmacy-and-beauty chain Boots to the Canadian arm of the Weston family for close to $9 billion, according to people familiar with the matter.
  • The discussions come as Sycamore looks to monetize assets after its 2025 acquisition and breakup of Walgreens Boots Alliance, though a deal is not certain and negotiations have reportedly slowed.
  • A sale would mark a significant cross-border bet on Boots' beauty platform and frontline health role, despite structural strains in U.K. community pharmacy.

Talks Underway

Sycamore Partners is in talks to sell Boots, the U.K.'s leading pharmacy-led health and beauty retailer, to the Canadian investment vehicle of the Weston family for close to $9 billion, according to people familiar with the matter. The discussions, first reported in June, identify Wittington Investments—whose portfolio includes Loblaw (L.TO) and Shoppers Drug Mart—as the prospective buyer. Australia's Sigma Healthcare (SIG.AX) was also reported to have held preliminary discussions, but later withdrew.

A subsequent report said negotiations had slowed after Sigma's exit and the Weston side reduced its bid, putting the probability of salvaging a deal at "50/50." That report is not an official confirmation, and no transaction is certain. Spokespeople for Sycamore and Wittington declined to comment.

The reported price range has varied: early accounts discussed roughly $10 billion, while more recent figures point to a deal close to $9 billion. That spread likely reflects evolving bids, valuation assumptions, and currency movements rather than a completed agreement.

A Breakup Strategy

The talks are part of Sycamore's early efforts to monetize assets after its 2025 acquisition of Walgreens Boots Alliance. The private-equity firm took the company private in a deal valued at up to $23.7 billion including debt, then split it into five stand-alone businesses: Walgreens, The Boots Group, VillageMD, CareCentrix, and Shields Health Solutions. That separation made Boots easier to sell as a standalone entity.

Boots operates more than 1,800 stores and employs over 51,000 people. It reported fiscal-2025 revenue of £7.5 billion, up 3.2% year on year, with pre-tax profit rising 25% to £337 million for the year ended August 2025. Beauty, including a broadened branded offer, was a key growth driver.

The contrast between growing retail profits and a difficult underlying pharmacy market is central to the valuation story. Boots' beauty and consumer-health businesses may command a premium, while its community-pharmacy activities face cost, reimbursement, workforce, and medicines-supply pressures.

Pharmacy Economics

U.K. pharmacy economics remain challenging. The government increased England's Community Pharmacy Contractual Framework funding to £3.073 billion for 2025–26, plus £215 million for Pharmacy First and related primary-care services. It also wrote off £193 million of historic medicine-margin over-delivery. These measures help the sector, but they do not eliminate broader profitability concerns.

An NHS-commissioned economic analysis found that 47% of pharmacy branches were unprofitable at EBITDA level in their latest accounting year, and concluded that sector-wide funding was below full economic cost. This makes scale, purchasing capability, prescription economics, store productivity, and cross-subsidy from beauty retail especially important to a buyer such as the Weston family.

Boots is integrated into England's community-pharmacy system, which is being asked to take on more clinical work to relieve GP and hospital pressure. Pharmacy First has already delivered more than 1.9 million consultations, while the 2025–26 framework supports wider contraception, hypertension, medicines-support, and selected remote-service reforms. A new owner would have to operate under NHS contractual requirements, medicines reimbursement rules, professional regulation, and competition law.

Cross-Border Considerations

A Weston acquisition would be a Canadian-controlled purchase of a large U.K. healthcare-retail asset. It would not inherently pose a major geopolitical issue, but it would bring competition and public-interest scrutiny because Boots is a nationally significant pharmacy provider. The family already owns Shoppers Drug Mart in Canada, so regulators would likely examine governance, supply arrangements, data controls, and any effects on pharmacy-market competition, though there is little direct overlap between the U.K. and Canadian retail pharmacy markets.

Boots has more than 175 years of history and became part of Walgreens through the Alliance Boots combination. Walgreens Boots Alliance faced intensifying pressure from lower-margin pharmacy operations, tougher retail competition, reimbursement constraints, and broader debt and restructuring concerns. A previous attempt to sell Boots had not produced a deal. More recently, Sycamore was reported to be considering an eventual London listing, but a direct sale could offer a faster and more certain exit if price expectations are met.

The closest precedent is not a one-for-one merger but the earlier consolidation of Boots into Alliance Boots and then Walgreens Boots Alliance: each reflected efforts to combine pharmacy scale with health-and-beauty retail. This time, however, the direction is reversed—separating a U.K. business from a U.S.-focused parent after a private-equity takeover.

What’s Next

The key question is whether Weston and Sycamore can bridge their valuation gap. A signed deal would likely require competition review and detailed financing, governance, and operational planning. If talks fail, Sycamore could retain Boots longer, seek other buyers, or revive an IPO route. Reported bidder interest from both Weston and Sigma indicates the asset has strategic appeal, but the apparent slowdown shows that interest has not automatically translated into an acceptable price.

Under a Weston-linked owner, Boots could be positioned as a U.K. counterpart to Shoppers Drug Mart: a large-format pharmacy, beauty, healthcare-services, loyalty, and digital-retail platform. Potential benefits include cross-border buying scale and retail-health expertise. The main risks are leverage, integration distraction, NHS funding uncertainty, pharmacy labour costs, medicines availability, online competition, and any branch closures that prompt public or political opposition.

Overall, a Boots sale near $9 billion would be a strategic bet that its valuable beauty brand, broad store network, and growing frontline-health role can generate durable returns despite the structural financial strain in community pharmacy.